Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Page standards status: Informative |
version: 90; Last updated: 2025-03-25 23:23:30+0000
Profile: ComparativeEvidenceSynthesisReport
Artifact Description:
Example of ComparativeEvidenceSynthesisReport Profile
url: https://fevir.net/resources/Composition/236538
identifier: FEvIR Object Identifier/https://fevir.net/FOI/236538, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparative-evidence-report-85390-85789
status: Final
type: Comparative Evidence Synthesis Report
date: 2025-03-25 23:23:30+0000
author: Qiukui Hao
title: ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk
custodian: Computable Publishing LLC
relatesTo
type: Part Of
target: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)
relatesTo
type: Cite As
target:
ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236538. Revised 2025-03-20. Available at: https://fevir.net/resources/Composition/236538. Computable resource at: https://fevir.net/FLI/DocumentForComposition236538.